SEC Filing - Bolt Biotherapeutics

SCHEDULE 13D

CUSIP No.

097702203

1

Name of reporting person

Nan Fung Group Holdings Limited

2

Check the appropriate box if a member of a Group (See Instructions)

(a)

(b)

3

SEC use only

4

Source of funds (See Instructions)

AF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

Checkbox not checked

6

Citizenship or place of organization

VIRGIN ISLANDS, BRITISH

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 128,119.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 128,119.00

11

Aggregate amount beneficially owned by each reporting person

128,119.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

Checkbox not checked

13

Percent of class represented by amount in Row (11)

6.7 %

14

Type of Reporting Person (See Instructions)

CO

SCHEDULE 13D

CUSIP No.

097702203

1

Name of reporting person

NF Investment Holdings Limited

2

Check the appropriate box if a member of a Group (See Instructions)

(a)

(b)

3

SEC use only

4

Source of funds (See Instructions)

AF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

Checkbox not checked

6

Citizenship or place of organization

VIRGIN ISLANDS, BRITISH

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 128,119.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 128,119.00

11

Aggregate amount beneficially owned by each reporting person

128,119.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

Checkbox not checked

13

Percent of class represented by amount in Row (11)

6.7 %

14

Type of Reporting Person (See Instructions)

CO

SCHEDULE 13D

CUSIP No.

097702203

1

Name of reporting person

Pivotal bioVenture Partners Fund I, L.P.

2

Check the appropriate box if a member of a Group (See Instructions)

(a)

(b)

3

SEC use only

4

Source of funds (See Instructions)

WC

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

Checkbox not checked

6

Citizenship or place of organization

CAYMAN ISLANDS

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 78,445.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 78,445.00

11

Aggregate amount beneficially owned by each reporting person

78,445.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

Checkbox not checked

13

Percent of class represented by amount in Row (11)

4.1 %

14

Type of Reporting Person (See Instructions)

PN

SCHEDULE 13D

CUSIP No.

097702203

1

Name of reporting person

Pivotal bioVenture Partners Fund I G.P., L.P.

2

Check the appropriate box if a member of a Group (See Instructions)

(a)

(b)

3

SEC use only

4

Source of funds (See Instructions)

AF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

Checkbox not checked

6

Citizenship or place of organization

CAYMAN ISLANDS

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 78,445.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 78,445.00

11

Aggregate amount beneficially owned by each reporting person

78,445.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

Checkbox not checked

13

Percent of class represented by amount in Row (11)

4.1 %

14

Type of Reporting Person (See Instructions)

PN

SCHEDULE 13D

CUSIP No.

097702203

1

Name of reporting person

Pivotal bioVenture Partners Fund I U.G.P. Ltd.

2

Check the appropriate box if a member of a Group (See Instructions)

(a)

(b)

3

SEC use only

4

Source of funds (See Instructions)

AF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

Checkbox not checked

6

Citizenship or place of organization

CAYMAN ISLANDS

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 78,445.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 78,445.00

11

Aggregate amount beneficially owned by each reporting person

78,445.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

Checkbox not checked

13

Percent of class represented by amount in Row (11)

4.1 %

14

Type of Reporting Person (See Instructions)

CO

SCHEDULE 13D

CUSIP No.

097702203

1

Name of reporting person

Pivotal Partners Ltd

2

Check the appropriate box if a member of a Group (See Instructions)

(a)

(b)

3

SEC use only

4

Source of funds (See Instructions)

AF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

Checkbox not checked

6

Citizenship or place of organization

CAYMAN ISLANDS

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 78,445.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 78,445.00

11

Aggregate amount beneficially owned by each reporting person

78,445.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

Checkbox not checked

13

Percent of class represented by amount in Row (11)

4.1 %

14

Type of Reporting Person (See Instructions)

CO

SCHEDULE 13D

CUSIP No.

097702203

1

Name of reporting person

Pivotal Life Sciences Holdings Limited

2

Check the appropriate box if a member of a Group (See Instructions)

(a)

(b)

3

SEC use only

4

Source of funds (See Instructions)

AF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

Checkbox not checked

6

Citizenship or place of organization

CAYMAN ISLANDS

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 78,445.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 78,445.00

11

Aggregate amount beneficially owned by each reporting person

78,445.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

Checkbox not checked

13

Percent of class represented by amount in Row (11)

4.1 %

14

Type of Reporting Person (See Instructions)

CO

SCHEDULE 13D

CUSIP No.

097702203

1

Name of reporting person

Nan Fung Life Sciences Holdings Limited

2

Check the appropriate box if a member of a Group (See Instructions)

(a)

(b)

3

SEC use only

4

Source of funds (See Instructions)

AF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

Checkbox not checked

6

Citizenship or place of organization

VIRGIN ISLANDS, BRITISH

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 123,119.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 123,119.00

11

Aggregate amount beneficially owned by each reporting person

123,119.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

Checkbox not checked

13

Percent of class represented by amount in Row (11)

6.4 %

14

Type of Reporting Person (See Instructions)

CO

SCHEDULE 13D

CUSIP No.

097702203

1

Name of reporting person

Permwell Management Limited

2

Check the appropriate box if a member of a Group (See Instructions)

(a)

(b)

3

SEC use only

4

Source of funds (See Instructions)

WC

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

Checkbox not checked

6

Citizenship or place of organization

CAYMAN ISLANDS

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 5,000.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 5,000.00

11

Aggregate amount beneficially owned by each reporting person

5,000.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

Checkbox not checked

13

Percent of class represented by amount in Row (11)

0.3 %

14

Type of Reporting Person (See Instructions)

CO

SCHEDULE 13D

CUSIP No.

097702203

1

Name of reporting person

NFLS Beta Limited

2

Check the appropriate box if a member of a Group (See Instructions)

(a)

(b)

3

SEC use only

4

Source of funds (See Instructions)

WC

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

Checkbox not checked

6

Citizenship or place of organization

VIRGIN ISLANDS, BRITISH

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 44,674.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 44,674.00

11

Aggregate amount beneficially owned by each reporting person

44,674.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

Checkbox not checked

13

Percent of class represented by amount in Row (11)

2.3 %

14

Type of Reporting Person (See Instructions)

CO

SCHEDULE 13D

CUSIP No.

097702203

1

Name of reporting person

NFLS Platform Holdings Limited

2

Check the appropriate box if a member of a Group (See Instructions)

(a)

(b)

3

SEC use only

4

Source of funds (See Instructions)

WC

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

Checkbox not checked

6

Citizenship or place of organization

CAYMAN ISLANDS

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 44,674.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 44,674.00

11

Aggregate amount beneficially owned by each reporting person

44,674.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

Checkbox not checked

13

Percent of class represented by amount in Row (11)

2.3 %

14

Type of Reporting Person (See Instructions)

CO

SCHEDULE 13D

Item 1.

Security and Issuer

(a)

Title of Class of Securities:

Common Stock, $0.00001 par value

(b)

Name of Issuer:

Bolt Biotherapeutics, Inc.

(c)

Address of Issuer's Principal Executive Offices:

900 Chesapeake Drive, Redwood City, CALIFORNIA , 94063.

Item 5.

Interest in Securities of the Issuer

(a)

Items 5(a)-(c) of the Schedule 13D are amended and restated as follows: The information set forth in rows 11 and 13 of the cover pages to this Schedule 13D is incorporated by reference. The percentage set forth in row 13 is based on 1,919,441 outstanding shares of Common Stock, as reported by the Issuer in its Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 12, 2025. In addition, Mr. Kam Chung Leung directly owns 8,684 shares of Common Stock.

(b)

The information set forth in rows 7 through 10 of the cover pages to this Schedule 13D is incorporated by reference.

(c)

Except as set forth on Schedule A, which is incorporated into this Item 5(c) by reference, no Reporting Person has effected any transaction in shares of Common Stock in the past sixty days.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Nan Fung Group Holdings Limited

Signature:	/s/ Tang Chun Wai Nelson
Name/Title:	Tang Chun Wai Nelson, Director
Date:	02/17/2026

NF Investment Holdings Limited

Signature:	/s/ Tang Chun Wai Nelson
Name/Title:	Tang Chun Wai Nelson, Director
Date:	02/17/2026

Pivotal bioVenture Partners Fund I, L.P.

Signature:	By Pivotal bioVenture Partners Fund I G.P., L.P.
Name/Title:	its General Partner
Date:	02/17/2026

Signature:	By Pivotal bioVenture Partners Fund I U.G.P., Ltd.
Name/Title:	its General Partner
Date:	02/17/2026

Signature:	/s/ Robert Hopfner
Name/Title:	Robert Hopfner, Authorized Signatory
Date:	02/17/2026

Pivotal bioVenture Partners Fund I G.P., L.P.

Signature:	By Pivotal bioVenture Partners Fund I U.G.P., Ltd.
Name/Title:	its General Partner
Date:	02/17/2026

Signature:	/s/ Robert Hopfner
Name/Title:	Robert Hopfner, Authorized Signatory
Date:	02/17/2026

Pivotal bioVenture Partners Fund I U.G.P. Ltd.

Signature:	/s/ Robert Hopfner
Name/Title:	Robert Hopfner, Authorized Signatory
Date:	02/17/2026

Pivotal Partners Ltd

Signature:	/s/ Sun Xintong
Name/Title:	Sun Xintong, Director
Date:	02/17/2026

Pivotal Life Sciences Holdings Limited

Signature:	/s/ Sun Xintong
Name/Title:	Sun Xintong, Director
Date:	02/17/2026

Nan Fung Life Sciences Holdings Limited

Signature:	/s/ Sun Xintong
Name/Title:	Sun Xintong, Director
Date:	02/17/2026

Permwell Management Limited

Signature:	/s/ Tang Chun Wai Nelson
Name/Title:	Tang Chun Wai Nelson, Director
Date:	02/17/2026

NFLS Beta Limited

Signature:	/s/ Sun Xintong
Name/Title:	Sun Xintong, Director
Date:	02/17/2026

NFLS Platform Holdings Limited

Signature:	/s/ Sun Xintong
Name/Title:	Sun Xintong, Director
Date:	02/17/2026


Fund	Date	Transaction	Number of shares	Price
Pivotal bioVenture Partners Fund I, L.P.	01/28/2026	Sale	3,257	$6.8348
NFLS Beta Limited	01/28/2026	Sale	1,343	$6.8502
Pivotal bioVenture Partners Fund I, L.P.	01/29/2026	Sale	2,612	$6.4524
NFLS Beta Limited	01/29/2026	Sale	1,488	$6.4524
Pivotal bioVenture Partners Fund I, L.P.	01/30/2026	Sale	1,657	$6.1325
NFLS Beta Limited	01/30/2026	Sale	943	$6.1325
Pivotal bioVenture Partners Fund I, L.P.	02/02/2026	Sale	1,402	$6.0495
NFLS Beta Limited	02/02/2026	Sale	798	$6.0495
Pivotal bioVenture Partners Fund I, L.P.	02/03/2026	Sale	319	$6.0141
NFLS Beta Limited	02/03/2026	Sale	182	$6.0141
Pivotal bioVenture Partners Fund I, L.P.	02/05/2026	Sale	2,867	$5.7272
NFLS Beta Limited	02/05/2026	Sale	1,633	$5.7272
Pivotal bioVenture Partners Fund I, L.P.	02/06/2026	Sale	1,720	$5.58
NFLS Beta Limited	02/06/2026	Sale	980	$5.58
Pivotal bioVenture Partners Fund I, L.P.	02/09/2026	Sale	510	$5.5139
NFLS Beta Limited	02/09/2026	Sale	290	$5.5139
Pivotal bioVenture Partners Fund I, L.P.	02/12/2026	Sale	510	$4.9606
NFLS Beta Limited	02/12/2026	Sale	290	$4.9606
Pivotal bioVenture Partners Fund I, L.P.	02/13/2026	Sale	1,274	$5.0073
NFLS Beta Limited	02/13/2026	Sale	726	$5.0073